Literature DB >> 30569130

Disruption of MAPK1 expression in the ERK signalling pathway and the RUNX1‑RUNX1T1 fusion gene attenuate the differentiation and proliferation and induces the growth arrest in t(8;21) leukaemia cells.

Salem Ali Al-Salem Bashanfer1, Mohamed Saleem2, Olaf Heidenreich3, Emmanuel Jairaj Moses4, Narazah Mohd Yusoff4.   

Abstract

The t(8;21) translocation is one of the most frequent chromosome abnormalities associated with acute myeloid leukaemia (AML). This abberation deregulates numerous molecular pathways including the ERK signalling pathway among others. Therefore, the aim of the present study was to investigate the gene expression patterns following siRNA‑mediated suppression of RUNX1RUNX1T1 and MAPK1 in Kasumi‑1 and SKNO‑1 cells and to determine the differentially expressed genes in enriched biological pathways. BeadChip microarray and gene ontology analysis revealed that RUNX1RUNX1T1 and MAPK1 suppression reduced the proliferation rate of the t(8;21) cells with deregulated expression of several classical positive regulator genes that are otherwise known to enhance cell proliferation. RUNX1RUNX1T1 suppression exerted an anti‑apoptotic effect through the overexpression of BCL2, BIRC3 and CFLAR genes, while MAPK1 suppression induced apopotosis in t(8;21) cells by the apoptotic mitochondrial changes stimulated by the activity of upregulated TP53 and TNFSF10, and downregulated JUN gene. RUNX1RUNX1T1 suppression supported myeloid differentiation by the differential expression of CEBPA, CEBPE, ID2, JMJD6, IKZF1, CBFB, KIT and CDK6, while MAPK1 depletion inhibited the differentiation of t(8;21) cells by elevated expression of ADA and downregulation of JUN. RUNX1RUNX1T1 and MAPK1 depletion induced cell cycle arrest at the G0/G1 phase. Accumulation of cells in the G1 phase was largely the result of downregulated expression of TBRG4, CCNE2, FOXO4, CDK6, ING4, IL8, MAD2L1 and CCNG2 in the case of RUNX1RUNX1T1 depletion and increased expression of RASSF1, FBXO6, DADD45A and P53 in the case of MAPK1 depletion. Taken together, the current results demonstrate that MAPK1 promotes myeloid cell proliferation and differentiation simultaneously by cell cycle progression while suppresing apoptosis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30569130     DOI: 10.3892/or.2018.6926

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

Review 1.  Regulation of Normal and Malignant Hematopoiesis by FBOX Ubiquitin E3 Ligases.

Authors:  R Willow Hynes-Smith; Karli J Wittorf; Shannon M Buckley
Journal:  Trends Immunol       Date:  2020-11-04       Impact factor: 16.687

2.  Personalized 3-Gene Panel for Prostate Cancer Target Therapy.

Authors:  Sanda Iacobas; Dumitru Andrei Iacobas
Journal:  Curr Issues Mol Biol       Date:  2022-01-15       Impact factor: 2.976

3.  Compound Kushen injection inhibits EMT of gastric cancer cells via the PI3K/AKT pathway.

Authors:  Luo Li; Keshan Wang; Zhenguo Liu; Yajuan Lü; Congcong Wang; Xuefei Yi; Jianping Guo
Journal:  World J Surg Oncol       Date:  2022-05-20       Impact factor: 3.253

4.  RBM24 exacerbates bladder cancer progression by forming a Runx1t1/TCF4/miR-625-5p feedback loop.

Authors:  Yue-Wei Yin; Kai-Long Liu; Bao-Sai Lu; Wei Li; Ya-Lin Niu; Chen-Ming Zhao; Zhan Yang; Ping-Ying Guo; Jin-Chun Qi
Journal:  Exp Mol Med       Date:  2021-05-21       Impact factor: 8.718

Review 5.  Wnt/β-catenin signaling pathway in uterine leiomyoma: role in tumor biology and targeting opportunities.

Authors:  Malak El Sabeh; Subbroto Kumar Saha; Sadia Afrin; Md Soriful Islam; Mostafa A Borahay
Journal:  Mol Cell Biochem       Date:  2021-05-17       Impact factor: 3.842

6.  Identified the Synergistic Mechanism of Drynariae Rhizoma for Treating Fracture Based on Network Pharmacology.

Authors:  Haixiong Lin; Xiaotong Wang; Ligang Wang; Hang Dong; Peizhen Huang; Qunbin Cai; Yingjie Mo; Feng Huang; Ziwei Jiang
Journal:  Evid Based Complement Alternat Med       Date:  2019-10-20       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.